Russia Pharmaceuticals & Healthcare Report Q2 2014 - New Report Available
A deteriorating macroeconomic picture and weakening rouble will moderate real pharmaceutical industry growth, as the consumer spending that currently underpins the pharmaceutical market loses momentum. Over the longer term, the country's ageing population and significant disease burden will act to underpin pharmaceutical expenditure growth. However, we are increasingly concerned about the sustainability of Russia's healthcare expenditure given its reliance on government oil and gas revenues, and underlying economic growth in light of the demographic trends that are playing out in...
View full press release